We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PerkinElmer's (PKI) New Assay Kits to Detect CHO HCP Impurities
Read MoreHide Full Article
PerkinElmer. Inc. recently launched two ready-to-use Homogenous Time Resolved Technology (HTRF) and AlphaLISA no-wash assay kits. These kits have been created to quickly and easily identify and quantify CHO host cell protein (HCP) impurities during biopharmaceutical manufacturing.
It is worth mentioning that these kits are the first on the market that have been developed to carry out the abovementioned function. Apart from this, these kits are easily automatable and can be miniaturized to a small sample volume, thereby substantially enhancing throughput to 384-well plates.
This announcement is likely to strengthen PerkinElmer’s robust product portfolio further.
Benefits of the Assays
Recombinant therapeutic proteins, like monoclonal antibodies, some vaccines and other biologics, must be free of residual HCP impurities to avert immunogenicity or lower potency, stability or overall effectiveness of a drug.
Per management, the capability to identify, quantify and eliminate CHO HCP impurities during the biopharmaceuticals manufacturing process continues to pose a challenge. These kits have been developed to make this important step more effective and efficient within existing workflows, thereby providing quality control and successful biotherapeutics.
Image Source: Zacks Investment Research
PerkinElmer can aid scientists with end-to-end workflow solutions, which range from early-stage drug discovery and development with assays, cell lines, microplates and plate readers to later-stage research and development with high-content screening, image analysis and data management, automated liquid handling and more through the addition of these assays.
Market Prospects
Per a report by Allied Market Research, the global biopharmaceuticals market was valued at $186,470 million in 2017 and is anticipated to reach $526,008 million by 2025, witnessing a CAGR of 13.8% from 2018 to 2025. Hence, this announcement comes at an opportune time for PerkinElmer.
Recent Developments
In March, PerkinElmer launched its FT-IR liquid food testing platform, including instruments, software and streamlined workflows. While the LQA300 TM FT-IR system leverages PerkinElmer’s FT-IR Spectroscopy technology, the LactoScope 300TM FT-IR system expands the company’s FT-IR dairy portfolio.
In the same month, the company announced a long-term collaboration with P1 Fuels — a specialist in the formulation, production and delivery of advanced, fossil-free performance fuels for racing teams and the automotive industry. Through this deal, PerkinElmer will work with P1 Fuels to aid the automotive sector, including motorsports, shift to climate-neutral, fossil-free fuels.
Price Performance
Shares of the Zacks Rank #3 (Hold) company have gained 26.2% in a year’s time compared with the industry’s rally of 7.3%.
Stocks to Consider
Some better-ranked stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , Edwards Lifesciences Corporation (EW - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 34.5% against the industry’s decline of 55.1% over the past year.
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 13.9%. EW’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 6.5%.
Edwards Lifesciences has appreciated 43.1% against the industry’s 0.2% fall over the past year.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2.
Henry Schein has surged 29.2% compared with the industry’s rally of 8.5% over the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
PerkinElmer's (PKI) New Assay Kits to Detect CHO HCP Impurities
PerkinElmer. Inc. recently launched two ready-to-use Homogenous Time Resolved Technology (HTRF) and AlphaLISA no-wash assay kits. These kits have been created to quickly and easily identify and quantify CHO host cell protein (HCP) impurities during biopharmaceutical manufacturing.
It is worth mentioning that these kits are the first on the market that have been developed to carry out the abovementioned function. Apart from this, these kits are easily automatable and can be miniaturized to a small sample volume, thereby substantially enhancing throughput to 384-well plates.
This announcement is likely to strengthen PerkinElmer’s robust product portfolio further.
Benefits of the Assays
Recombinant therapeutic proteins, like monoclonal antibodies, some vaccines and other biologics, must be free of residual HCP impurities to avert immunogenicity or lower potency, stability or overall effectiveness of a drug.
Per management, the capability to identify, quantify and eliminate CHO HCP impurities during the biopharmaceuticals manufacturing process continues to pose a challenge. These kits have been developed to make this important step more effective and efficient within existing workflows, thereby providing quality control and successful biotherapeutics.
Image Source: Zacks Investment Research
PerkinElmer can aid scientists with end-to-end workflow solutions, which range from early-stage drug discovery and development with assays, cell lines, microplates and plate readers to later-stage research and development with high-content screening, image analysis and data management, automated liquid handling and more through the addition of these assays.
Market Prospects
Per a report by Allied Market Research, the global biopharmaceuticals market was valued at $186,470 million in 2017 and is anticipated to reach $526,008 million by 2025, witnessing a CAGR of 13.8% from 2018 to 2025. Hence, this announcement comes at an opportune time for PerkinElmer.
Recent Developments
In March, PerkinElmer launched its FT-IR liquid food testing platform, including instruments, software and streamlined workflows. While the LQA300 TM FT-IR system leverages PerkinElmer’s FT-IR Spectroscopy technology, the LactoScope 300TM FT-IR system expands the company’s FT-IR dairy portfolio.
In the same month, the company announced a long-term collaboration with P1 Fuels — a specialist in the formulation, production and delivery of advanced, fossil-free performance fuels for racing teams and the automotive industry. Through this deal, PerkinElmer will work with P1 Fuels to aid the automotive sector, including motorsports, shift to climate-neutral, fossil-free fuels.
Price Performance
Shares of the Zacks Rank #3 (Hold) company have gained 26.2% in a year’s time compared with the industry’s rally of 7.3%.
Stocks to Consider
Some better-ranked stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , Edwards Lifesciences Corporation (EW - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 34.5% against the industry’s decline of 55.1% over the past year.
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 13.9%. EW’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 6.5%.
Edwards Lifesciences has appreciated 43.1% against the industry’s 0.2% fall over the past year.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2.
Henry Schein has surged 29.2% compared with the industry’s rally of 8.5% over the past year.